Click on the session titles to view the recordings.
View the Agenda and Recorded TalksThis tool is designed to help institutional leaders, clinicians, and support staff to understand the bispecific landscape, identify barriers to adoption, and evaluate ways to overcome challenges to successfully operationalize these agents to support patient access.
This tool:
Uses a 1-7 scale for each area related to BsAb operationalization to help evaluate program readiness/operationalization with 1 indicating a component that has not yet been initiated and 7 indicating an optimized program in this area.
Includes discussion questions to prompt reflection, informing ratings and next steps.
Can be used more than once to evaluate progress over time and identify areas for continual improvement.
This strategy report outlines five actionable priorities to improve bladder cancer care across health systems. It also focuses on patient education, care coordination, referral pathways, provider knowledge, and program measurement. The report addresses the challenges posed by high recurrence rates, complex patient populations, and evolving therapies, highlighting the need for standardized, guideline-concordant care. Published - April 2026
The Time Back campaign for cancer care honors oncologists, the emotional burdens they carry, and the work they do to help make more moments possible for people living with cancer.
To learn more visit, BMS.com.Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
ASCENT-04 published in New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2508959
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
ASCENT-03 published in New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2511734
Pfizer and the American Cancer Society are teaming up through Change the Odds to help break barriers in cancer care disparities with a focus on: Cancer Screening, Patient Resources & Support, and Clinical Trials. Learn more below.
This brochure from Regeneron provides helpful information on advanced CSCC and advanced BCC in patients of color.
Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions. View the full press release.
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program. View the full press release.
Posted on 01/15/2026
View the full publication:
View the Plain Language Summary of the publication
© Johnson & Johnson and its affiliates 2025. 12/25 CP-557697v1